Senti Biosciences Files 8-K on Shareholder Votes & Financials

Ticker: SNTI · Form: 8-K · Filed: Mar 7, 2025 · CIK: 1854270

Sentiment: neutral

Topics: 8-K, corporate-governance, financial-reporting

TL;DR

Senti Bio filed an 8-K for shareholder votes and financials as of March 6, 2025.

AI Summary

Senti Biosciences, Inc. filed an 8-K on March 7, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing pertains to events occurring on March 6, 2025. The company, incorporated in Delaware, is based in South San Francisco, California.

Why It Matters

This 8-K filing provides updates on important corporate actions and financial reporting, which are crucial for investors to understand the company's governance and financial health.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of corporate actions and financial information, not indicating any immediate operational or financial distress.

Key Numbers

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not elaborated in the provided text.

What financial statements are included in this filing?

The filing lists 'Financial Statements and Exhibits' as an item, but the specific financial statements are not detailed in the provided text.

When was Senti Biosciences, Inc. incorporated?

Senti Biosciences, Inc. was incorporated in Delaware.

What is the principal executive office address of Senti Biosciences, Inc.?

The principal executive offices are located at 2 Corporate Drive, First Floor, South San Francisco, California 94080.

What is the telephone number for Senti Biosciences, Inc.?

The registrant's telephone number is (650) 239-2030.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 7, 2025 regarding Senti Biosciences, Inc. (SNTI).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing